Research seeks to prevent vision loss in infants with congenital glaucoma

Without treatment, congenital glaucoma can lead to vision loss, often before a baby ever takes his first steps.

Unraveling how this eye disease occurs is the goal of Colleen McDowell, PhD, Research Assistant Professor of Cell Biology and Immunology. A $60,000 grant from the Knights Templar Eye Foundation is funding her research on this condition that affects one in every 10,000 infants.

Unlike most types of glaucoma that develop slowly and occur late in life, congenital glaucoma is present at birth, develops quickly and is much more severe, Dr. McDowell said.

Normally fluid leaves a healthy eye through a tiny drain. The eye then makes more fluid to replace what is lost. But this balance is thrown off in an eye with glaucoma because the fluid does not drain properly.

“With congenital glaucoma, pressure in the eye gets really high, really fast,” Dr. McDowell said. “In small children this ends up killing cells in the back of the eyes that are responsible for vision.”

Her research will focus on pinpointing the cells that are dying first.

“If I can identity those that are dying the fastest, then it’s possible to target and save those cells first,” she said. “That can hopefully lead to therapies that prevent the death of the cells that are responsible for vision loss.”

The symptoms, which might not be apparent at birth, include light sensitivity and excessive tearing caused by malfunctions in the drainage system. Often the child’s eyes are unusually large because of high pressure building up, Dr. McDowell said.

If the disease is diagnosed early, structural damage can be treated with surgery and most children do well. But once vision is lost, it cannot be restored.

Dr. McDowell hopes that her research will lead to therapies that help prevent vision loss in children with the disease.

The Knights Templar Eye Foundation’s pediatric ophthalmology grants support researchers at the beginning of their careers who are committed to the prevention and cure of potentially blinding eye diseases in infants and children.

To date, it has directed more than $23 million to such research efforts.

Recent News

Techstars Demo Day.
  • On Campus
|Dec 1, 2022

Techstars Demo Day brings innovation to the historic stockyards

For the last 13 weeks, the founders of 10 of the world’s most innovative startups have been in Fort Worth perfecting their new physical health technology. They are part of the world’s first physical health accelerator, and now they are ready to show the fruits of their labor. Techstars Demo D...
Dr. Sid O'bryant Award
  • Our People
|Dec 1, 2022

HSC named the winner of the D Magazines 2022 Achievement in Medical Research Award

The extensive research done by Dr. Sid O’Bryant and his team at the Institute of Translational Research has earned the University of North Texas Health Science Center at Fort Worth the 2022 Medical Research Award by D Magazine. Dr. O’Bryant, the executive director of the ITR and a professor at t...
Dr. John Licciardone
  • Our People
|Nov 30, 2022

Key study results from HSC’s PRECISION Pain Research Registry published in JAMA Network Open

The Journal of the American Medical Association – Network Open has published findings from a recent HSC study about chronic lower back pain, race and the patient-physician relationship. The study revealed that Black patients reported worse outcomes for low back pain intensity and back-related d...
Ram flyer
  • Community
|Nov 23, 2022

Free pop-up medical, vision and dental clinic is just a week away

  The University of North Texas Health Science Center at Fort Worth and Remote Area Medical – RAM® — a nonprofit provider of pop-up clinics that delivers free quality dental, vision and medical care to those in need — are bringing the free health care clinic to Dallas on Dec. 3 and 4....